Table 1. Characteristics of the 135 subjects at 0 (baseline), 3 and 6 months after initiation of the intervention.
| Baseline | 3 months | P-value | 6 months | P-value | |
|---|---|---|---|---|---|
| Age | 40.9±5.1 | ||||
| Weight (kg) | 79.4±11.8 | 77.0±11.5 | <0.001 | 76.4±11.6 | <0.001 |
| BMI (kg m−2) | 26.9±3.6 | 26.1±3.6 | <0.001 | 25.9±3.6 | <0.001 |
| Abdominal circumference (cm) | 94.1±8.9 | 91.4±9.0 | <0.001 | 90.5±9.5 | <0.001 |
| % fat (%) | 26.6±5.4 | 24.6±4.7 | <0.001 | 24.4±4.8 | <0.001 |
| Fat mass (kg) | 21.6±7.5 | 19.4±6.7 | <0.001 | 19.1±6.8 | <0.001 |
| SBP (mm Hg) | 121.6±12.4 | 121.9±11.9 | 0.523 | 121.7±12.3 | 0.992 |
| DBP (mm Hg) | 72.4±10.3 | 76.6±9.9 | <0.001 | 75.4±10.6 | <0.001 |
| TG (mg per 100 ml) | 149.8±114.2 | 122.6±71.7 | <0.001 | 136.2±116.3 | 0.009 |
| HDL-C (mg per 100 ml) | 58.4±13.2 | 55.5±12.1 | <0.001 | 57.1±12.8 | 0.051 |
| LDL-C (mg per 100 ml) | 134.8±35.3 | 125.1±31.0 | <0.001 | 126.7±33.2 | <0.001 |
| LDL-C/HDL-C | 2.43±0.84 | 2.39±0.86 | 0.166 | 2.35±0.89 | 0.155 |
| FPG (mg per 100 ml) | 99.9±12.0 | 96.3±9.7 | <0.001 | 96.3±9.9 | <0.001 |
| HbA1c (%) | 5.38±0.45 | 5.20±0.36 | <0.001 | 5.22±0.35 | <0.001 |
| Insulin (mcU ml-1) | 10.12±9.17 | 7.37±5.14 | <0.001 | 8.09±5.74 | <0.001 |
| HOMA-IR | 2.57±2.71 | 1.79±1.37 | <0.001 | 1.96±1.49 | <0.001 |
| AST (IU l−1) | 25.5±9.0 | 22.2±8.5 | <0.001 | 23.0±8.7 | 0.005 |
| ALT (IU l−1 | 37.1±21.9 | 28.6±15.9 | <0.001 | 30.0±20.2 | <0.001 |
| Hs-CRP (mg per 100 ml) | 0.086±0.156 | 0.086±0.125 | 0.907 | 0.090±0.120 | 0.811 |
| Angptl2 (ng ml−1) | 3.02±1.18 | 2.79±1.11 | 0.001 | 2.65±1.08 | <0.001 |
| Adiponectin (mcg ml−1) | 6.59±3.78 | 6.22±3.94 | <0.001 | 6.45±3.93 | 0.108 |
Abbreviations: Angptl2, angiopoietin-like protein 2; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; DBP, diastolic blood pressure; FPG, fasting plasma glucose; HbA1c, hemoglobin A1c; HOMA-IR, homeostasis model assessment of the insulin resistance index; Hs-CRP, high sensitive C-reactive protein; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure; TG, triglyceride.
Data are presented as means±s.d. Statistical differences of clinical and laboratory data at the 3- and 6-month time points compared with baseline values were examined using the Wilcoxon signed rank test.